Aglaia Oncology Funds
The Dutch venture capital firm Aglaia – through its Oncology Funds I and II – invests in ground-breaking technologies that have the potential to translate into solutions for the prevention and treatment of cancer. Aglaia is actively involved in the companies it invests in and works closely with scientists and management teams in the early stages of technological development. By translating high-potential research into commercially and clinically successful products Aglaia gives meaning to the concept of impact investing; combining financial and social returns.
BioGeneration Ventures invests in seed and early stage Dutch Life Sciences companies. BioGeneration’s team specialises in developing the value of novel and innovative technologies, and in the management of start-up companies. BioGeneration Ventures was co-founded by the Netherlands Genomics Initiative (NGI), Netherlands Organisation for Scientific Research (NWO), the Holding of the University of Leiden, and ABN-AMRO. BioGeneration Ventures cooperates closely with Forbion Capital Partners.
Brabant Development Agency
Brabant Development Agency (BOM) is an economic development company that invests in seed, early stage and scale-up companies with a strong link to Brabant. Together with a network of partners, BOM provides knowledge, capital, talent, market and facilities to innovative companies with strong growth ambitions and the potential to achieve economic and social impact. In this way BOM contributes to an innovative and resilient Brabant economy.
Chemelot Ventures is a venture capital investor in Life Sciences (including drug delivery) and Performance Materials (including polymers). The company aims to further strengthen hubs in these industries on and around the Chemelot Campus and Maastricht Health Campus, two leading European research hubs. Chemelot Ventures continues to actively support its portfolio companies after it has made its investment, drawing on its extensive network in the financial world, the industry and the region. Chemelot Ventures is the successor fund of Limburg Ventures which started in 2004 and made 22 investments.
Droia Oncology Ventures
DROIA is a venture capital investor focusing exclusively on oncology therapeutics. Operating from Luxembourg and Belgium, DROIA invests worldwide in early-stage drug development companies that apply novel science and innovative approaches to bring highly promising drug candidates to patients. Through its experienced team of in-house scientists and drug developers, DROIA also supports young companies on scientific and development matters. Funded by private investors, DROIA is dedicated to making a difference in the fight against cancer.
LIOF, the Limburg Development and Investment Company, works to promote economic development in the Dutch province of Limburg. LIOF supports companies in terms of innovation, development, and investments; and helps them to set up business. Alongside this, LIOF creates favourable business conditions which allow high-potential sectors to develop. This involves in particular creating opportunities for small to medium-sized businesses (SME’s) and providing space for new business activity. LIOF provides enterprises with pragmatic, committed, and proactive support by combining its expertise with financial vigour and an extensive network of contacts. This combination of services makes LIOF a unique and dynamic partner to work with.
LIOF has three financial instruments to support the SME’s in Limburg: LBDF Seed Fund (for high-tech start-ups), the Participation Fund and the SME Loan Fund.
Thuja Capital is an independent venture capital firm focussed on investments in Benelux based early stage companies that aim to develop medical product innovations for prevention, diagnosis, cure or care. Such products include therapeutics, diagnostics, and medical devices, to deliver both healthcare return as well as financial return. Thuja Capital leverages its long-standing experience and extensive network to actively support portfolio companies to strengthen and grow their business.
Utrecht Holdings is responsible for the patent portfolio and technology transfer activities of Utrecht University and the University Medical Center Utrecht. Utrecht Holdings has started and invested in over 30 spin-out companies and currently holds equity in 24 of those companies. Utrecht Holdings assigned ownership of the CriPec® technology to Cristal Therapeutics, which brings the results of academic research into biotech development to design effective therapeutics for patients. Utrecht Holdings also invested capital in Cristal Therapeutics.